Roquefort Therapeutics (ROQ) News Today GBX 1.52 -0.23 (-12.86%) As of 08/1/2025 08:22 AM Eastern Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock ROQ Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Stephen Paul West Purchases 2,400,000 Shares of Roquefort Therapeutics plc (LON:ROQ) StockJuly 8, 2025 | insidertrades.comInsider Buying: Roquefort Therapeutics plc (LON:ROQ) Insider Buys 72,507 Shares of StockJuly 1, 2025 | insidertrades.comRoquefort Thera Share Chat (ROQ)June 21, 2025 | lse.co.ukSMALL-CAP WINNERS & LOSERS: Roquefort jumps on Oncogeni dealMarch 10, 2025 | lse.co.ukRoquefort Therapeutics CEO resigns, agrees terms for Oncogeni disposalMarch 10, 2025 | lse.co.ukSMALL CAP IDEA: Roquefort finds pharma diamonds in the roughFebruary 10, 2025 | msn.comStephen Paul West Buys 400,000 Shares of Roquefort Therapeutics plc (LON:ROQ) StockFebruary 5, 2025 | insidertrades.comRoquefort Therapeutics proposes USD10 million subsidiary saleJanuary 2, 2025 | lse.co.ukGlycoMimetics, Inc. (GKO.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 24, 2024 | finance.yahoo.comRoquefort Therapeutics says MK cell therapy patent approved in JapanSeptember 24, 2024 | lse.co.ukTG Therapeutics, Inc. (TGTX)August 10, 2024 | finance.yahoo.comRoquefort Therapeutics PLC ROQMay 29, 2024 | morningstar.comMEARNINGS AND TRADING: Aura confident in Tiris; Cindrigo enters GermanyApril 26, 2024 | lse.co.ukUK Stocks: Here’s Why Roquefort (ROQ) Share Price is CrashingApril 5, 2024 | msn.comRoquefort celebrates "significant milestones" in cancer researchMarch 11, 2024 | lse.co.ukRoquefort Therapeutics reveals progress with liver and colorectal cancer programmesMarch 11, 2024 | uk.investing.comNBSE NeuBase Therapeutics, Inc.December 21, 2023 | seekingalpha.comRoquefort Therapeutics MK cell programme shows positive resultsNovember 6, 2023 | lse.co.ukRoquefort Therapeutics preparing targets for clinic as eyes commercial dealsSeptember 27, 2023 | proactiveinvestors.comRoquefort Therapeutics preparing targets for clinic as it eyes commercial dealsSeptember 27, 2023 | proactiveinvestors.comRoquefort Therapeutics seeks to lock in future value with anti-cancer therapeutic patentsAugust 17, 2023 | finance.yahoo.comRoquefort Therapeutics making headway with siRNAAugust 9, 2023 | finance.yahoo.comRoquefort Therapeutics highlights significant progress at AGMJune 29, 2023 | proactiveinvestors.comRoquefort Therapeutics hails significant pre-clinical resultsJune 22, 2023 | proactiveinvestors.comRoquefort Therapeutics Makes Progress on Cancer TreatmentJune 22, 2023 | marketwatch.comRoquefort Therapeutics returns to the market with new study dataJune 16, 2023 | finance.yahoo.comRoquefort Therapeutics' Anti-Cancer MRNA Study Showed Positive ResultsJune 13, 2023 | marketwatch.comRoquefort Therapeutics Resumes Trading After Publishing 2022 ResultsJune 7, 2023 | marketwatch.comRoquefort Therapeutics eyes second half progressJune 5, 2023 | proactiveinvestors.comRoquefort Therapeutics has no exposure to SVBMarch 13, 2023 | proactiveinvestors.comRoquefort Therapeutics says new mRNA platform "fits very well"March 8, 2023 | proactiveinvestors.comRoquefort develops a fifth programme using a technology pioneered by Moderna and BioNTechMarch 8, 2023 | proactiveinvestors.comRoquefort Therapeutics establishes scientific advisory boardMarch 6, 2023 | proactiveinvestors.comRoquefort Thera Regulatory NewsFebruary 22, 2023 | lse.co.ukRoquefort Therapeutics PLCFebruary 21, 2023 | barrons.comRoquefort Therapeutics inks Randox diagnostic dealFebruary 20, 2023 | proactiveinvestors.comRoquefort Therapeutics inks first strategic licensing deal with diagnostics firm RandoxFebruary 20, 2023 | proactiveinvestors.comRoquefort Therapeutics demonstrates initial safety in two antibody programmesJanuary 26, 2023 | finance.yahoo.comRoquefort Therapeutics demonstrates safety in two antibody programmesJanuary 24, 2023 | proactiveinvestors.comRoquefort Therapeutics cancer drugs enjoy pre-clinical successJanuary 24, 2023 | proactiveinvestors.comRoquefort Therapeutics CEO lays out strategy for 2023January 9, 2023 | proactiveinvestors.comRoquefort Therapeutics in out-licensing discussions with 'multiple' large bio-pharma companiesJanuary 9, 2023 | proactiveinvestors.comRoquefort Therapeutics to present breakthrough RNA cancer study results at key conferenceOctober 11, 2022 | proactiveinvestors.comRoquefort Therapeutics explains the significance of its "very exciting" cancer drug study resultsOctober 11, 2022 | proactiveinvestors.comStratford-upon-Avon company bought in multi-million pound dealSeptember 21, 2022 | msn.comBiotech firm Oncogeni acquired in £5.5m dealSeptember 20, 2022 | msn.comUK Retailers Drop After August Sales SlumpSeptember 17, 2022 | morningstar.comMRoquefort enlists Nobel prizewinner Sir Martin EvansSeptember 16, 2022 | thetimes.co.ukTFTSE 100 opens lower as world bank warns of recession.September 16, 2022 | proactiveinvestors.comRoquefort Therapeutics plc (ROQ.L)September 2, 2022 | uk.finance.yahoo.com Get Roquefort Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ROQ and its competitors with MarketBeat's FREE daily newsletter. Email Address ROQ Media Mentions By Week ROQ Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ROQ News Sentiment▼0.000.63▲Average Medical News Sentiment ROQ News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ROQ Articles This Week▼00▲ROQ Articles Average Week Get Roquefort Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ROQ and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies FAB News HEMO News DEST News VAL News ONC News PYC News ONT News GNS News PRTC News OXB News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:ROQ) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roquefort Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Roquefort Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
